Nellix Endovascular Aneurysm Sealing System (EVAS): A New Concept in Endovascular Repair - What the Radiologist Needs to Know

Weller A1*, Shah AM2, Seyed AR2, Touska P1, Sayer C2 and Vlahos I1

1. Two balloon expandable stainless steel endoframes maintain a seal proximally and distally. Each fills via an injection system at the caudal end.

2. A non-porous polyfluoroethylene (PTFE) - based endobag surrounds the endoframe and contains polymer. The endobags mould to the aneurysm sac lumen and provide a seal proximally and distally. Each fills via an injection system at the caudal end.

Keywords: Endovascular repair; Radiology; Abdominal aortic aneurysm; CT; Complications

Introduction

Clinical use of the Nellix endovascular aneurysm sealing system (EVAS) (Endologix, Santa Rosa, CA) for the treatment of infrarenal aortic aneurysms began in 2009 with promising early results. Until recently, all aortic endografts have had similar design morphology, typically of a bifurcated fabric-stent with proximal and distal attachments that fix and seal the device to the non-aneurysmal aorta and the iliac arteries. However, there are ongoing concerns regarding the long term outcomes of these devices, with migration, endo-leaks, aneurysm enlargement and rupture all potential risks [1-4]. Up to 2009, the infra-renal devices approved by the United States Food and Drug Administration (FDA) and European Medicines Agency (EMA) all achieved seal and longitudinal fixation through hooks, barbs, suprarenal stents, radial force and columnar rigidity [5-8].

In contrast, the sac anchoring EVAS comprises two balloon expandable stents that extend in parallel from the non-aneurysmal aorta proximally into the iliac arteries distally, each surrounded by a polymer filled endobag. The endobags obliterate the aneurysm lumen to achieve a seal and, in vitro and in theory, resist both lateral and longitudinal displacement forces. This device has FDA Investigational Device Exemption as well as European CE Mark approval and is currently undergoing clinical trial for efficacy [available at http://www.endologix.com/ investigational_devices/nellix/clinical.php].

Although still undergoing evaluation for efficacy in infrarenal aneurysms with morphology suitable for conventional endovascular aneurysm repair (EVAR) devices, the Nellix device is potentially suitable for a wider range of aneurysmal anatomies than conventional EVAR systems. The aim of this pictorial review is to discuss the features of the Nellix EVAS, specifically with regard to the imaging findings post implantation that radiologists may encounter during follow-up imaging. Images of early complications after Nellix EVAS are also presented.

Nellix Endografts Device Description and Insertion Procedure

The Nellix EVAS comprises twin identical catheter based systems, one inserted on each side, and each with four components (Figure 1):
3. Biocompatible polyethylene glycol (PEG) based polymer fills the endobag and is mixed with iodinated contrast agent for visibility under fluoroscopy. The polymer, liquid when mixed, cures to a rubbery solid in ≤5 min at 37°C. An injection system monitors fill volume and pressure.

4. 17 Fr (external diameter) tapered nose delivery catheters, inserted via the femoral arteries, contain the endoframe, the surrounding endobag and ports for polymer injection, as well as ports for 0.035” guidewire insertion, balloon inflation and angiography.

Device insertion is performed under fluoroscopic guidance (Figure 2) and once in position in the aorta, the two introduction catheters are simultaneously manipulated in the following steps [9]: (a) the endobag and fill-line integrity is confirmed by creating a vacuum through the system; (b) the stents are simultaneously balloon expanded; (c) mixed polymer solution is introduced to the endobags under volume and pressure monitoring; and (d) check angiography performed to assess stent position and patency of renal vessels.

**Nellix Inclusion Criteria for Insertion and Anatomical Limitations**

The Nellix inclusion criteria covered by the manufacturer instructions for use (IFU) are as described in Table 1 and Figure 3 and include a greater range of infra-renal aortic aneurysm anatomies than other conventional EVAR devices are currently available [10]. However, unlike for conventional EVAR, juxta- and supra-renal aneurysms are not suitable for treatment with Nellix according to the current IFU and treatment of these aneurysms is not currently routine. The most commonly encountered anatomic limitation within the Nellix IFU for infra-renal aneurysms is a 60mm maximum patent aortic lumen diameter, due to constraints in maximum endobag expansion. Despite this barrier, a recent retrospective survey of infra-renal EVAR showed Nellix to be suitable for up-to 70% of patients presenting for elective AAA repair, making Nellix applicable to a greater proportion of patients with infrarenal AAs than other conventional stent grafts [9]. The main potential advantages of the Nellix device compared with conventional infrarenal devices are listed in Table 2.

**Pre-Procedure Planning and Follow up Imaging Protocol**

As for conventional EVAR, CT angiography is performed for pre-procedure planning due to its exquisite anatomical detail. At this time, all patients eligible under the inclusion criteria for standard infra-renal EVAR may be considered for the Nellix device, although with minor differences in treatable infra-renal aortic aneurysm anatomies as described in Table 1 (different proximal neck diameter, length and angulation, common iliac artery diameter, length and tortuosity). With increasing experience of this device, these inclusion criteria may change, potentially enabling patients with more adverse neck and iliac artery anatomy to be treated with the Nellix EVAS. As stated previously, the flow lumen of the aneurysm should be evaluated and should be less than 60mm diameter.

Rational imaging surveillance imaging post conventional EVAR is dictated by the need to detect endoleaks, device migration, and include a greater range of infra-renal aortic aneurysm anatomies as described in Table 1 (different proximal neck diameter, length and angulation, common iliac artery diameter, length and tortuosity). With increasing experience of this device, these inclusion criteria may change, potentially enabling patients with more adverse neck and iliac artery anatomy to be treated with the Nellix EVAS. As stated previously, the flow lumen of the aneurysm should be evaluated and should be less than 60mm diameter.

---

**Table 1:** Nellix instructions for use (IFU), compared with FDA and EMA approved conventional EVAR systems. Nellix manufacturer IFU include: short aneurysm neck (constrained endobag expansion).

<table>
<thead>
<tr>
<th>Dims (mm)</th>
<th>Gore Excluder</th>
<th>Cook Zenith</th>
<th>Gore Excluder Low Perm</th>
<th>Endologix Powerlink</th>
<th>Cook Zenith Enlarged Neck</th>
<th>Medtronic Talent</th>
<th>Endologix Enlarged Neck</th>
<th>Gore Excluder Enlarged Neck</th>
<th>Summary of EVARs</th>
<th>Endologix Nellix</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neck Length</td>
<td>≥15</td>
<td>≥15</td>
<td>≥15</td>
<td>≥15</td>
<td>≥15</td>
<td>≥10</td>
<td>≥15</td>
<td>≥15</td>
<td>≥10-15</td>
<td>≥10</td>
</tr>
<tr>
<td>Neck Angle</td>
<td>≤60°</td>
<td>≤60°</td>
<td>≤60°</td>
<td>≤60°</td>
<td>≤60°</td>
<td>≤60°</td>
<td>≤60°</td>
<td>≤60°</td>
<td>≤60°-60°</td>
<td>≤60°</td>
</tr>
<tr>
<td>Iliac fixation length</td>
<td>≥10</td>
<td>≥15</td>
<td>≥10</td>
<td>≥10</td>
<td>≥15</td>
<td>≥15</td>
<td>≥15</td>
<td>≥10</td>
<td>≥10-15</td>
<td>N/A</td>
</tr>
<tr>
<td>Iliac Diam</td>
<td>10-18.5</td>
<td>10-20</td>
<td>10-18.5</td>
<td>10-18.5</td>
<td>8-18</td>
<td>8-22</td>
<td>10-23</td>
<td>10-18.5</td>
<td>8-23</td>
<td>8-35</td>
</tr>
</tbody>
</table>

**Table 2:** Nellix advantages and disadvantages over conventional EVAR.

<table>
<thead>
<tr>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Position at the top of the aneurysm sac rather than in the aneurysm neck for short necked or sharply angulated necks (avoids neck angulation).</td>
<td>Anatomic limitation: Maximum 60 mm patent aortic aneurysm lumen diameter (constrained endobag expansion).</td>
</tr>
<tr>
<td>Sac anchoring device, resisting lateral displacement and hence reduced migration risk in vitro.</td>
<td>Lack of data supporting use in juxta- and supra-renal aneurysms.</td>
</tr>
<tr>
<td>The endobags seal side branch flow (lower risk of Type 2 endoleaks).</td>
<td>Current uncertainty about the frequency and natural history of complications - long term outcomes data is pending.</td>
</tr>
<tr>
<td>Easier deployment with smaller diameter deployment catheters.</td>
<td></td>
</tr>
<tr>
<td>Simplified treatment of common iliac artery aneurysms (obliterates aneurysm sac whilst preserving flow to EIA and IIA without need for IIA embolization).</td>
<td></td>
</tr>
</tbody>
</table>
sac enlargement and possible rupture [11-14]. Experience with Nellix endografts is limited to relatively small reported case series, requiring further study before representative long term outcomes and complication rates are determined [15]. As a result, rational follow up imaging protocols are yet to be drafted. The surveillance imaging adopted by operators using the Nellix device has so far followed protocols used for conventional EVAR devices; computed tomography angiography (CTA) at 1, 6 and 12 months and annually thereafter.

**Initial Observations on Follow up Imaging**

On serial CT scans following uncomplicated Nellix EVAS, the most striking feature is a gradually reducing CT density of the endobag polymer over the first weeks to months post insertion (Figure 4). This happens at a variable rate. Immediately after the procedure, the Nellix PEG polymer is denser than sac thrombus, in keeping with a solid solution containing iodinated contrast medium introduced during deployment. Within 3-4 months, this overall increased density fades and a rim of high density emerges at the interface between the PEG polymer and hydrophobic surfaces (adjacent to the endobag gas locules and PTFE walls). In previous series, the reducing density was attributed to dissolution of iodinated contrast from the Nellix polymer [16,17]. However, in our experience, the concomitant developing high density rim surrounding the polymer suggests, rather than contrast dissolution; these changes represent iodinated contrast displacement from within the polymer to collect at the interface with PTFE or air.

Another striking feature following Nellix EVAS is of air locules that are frequently introduced to the endobag (and to a lesser extent into the aneurysm sac) during device deployment; these locules resorb within the first weeks, contemporaneous with the reducing CT density of the endobag polymer (Figure 4). On visual assessment of serial CT studies, the overlying endobag wall remains inflated in most cases and the resorbed air is replaced by material of density 20-30 HU, lower than the endobag polymer. However, in some cases, the endobag wall cannot be differentiated from underlying polymer and it is possible that the endobag collapses down into the defect previously occupied by air. It is at present unclear whether these latter features are associated with increased risk of type 1 or type 2 endoleaks.

A historic observation reported in 7 of the first 10 patients from the very first series of Nellix devices inserted, was of a non enhancing ring, or halo, located immediately between the endoframe and endobag on CT at 1 and 6 months. This finding was not associated with any change in aneurysm morphology or adverse clinical events. Following changes to the early endobag design, the halo was not seen in subsequent patients, suggesting that it reflected large endobag lumen diameter relative to the endoframe [17]. In our institution, using a more recent endobag design, we have not observed this feature.

**Initial Nellix Outcomes and Complications**

Initial clinical experience with Nellix, from 2009 to 2014, has yielded promising short-term results [17]. However, despite the potential suitability of a greater proportion of aneurysm anatomies for treatment within the Nellix IFU compared with conventional EVAR, current clinical experience and patient follow-up are limited. This requires larger case control studies for clinical and technical outcomes assessment before efficacy is confirmed and widespread adoption is justified.

Complications are most frequently diagnosed on follow-up imaging (with either Duplex ultrasound or CT) and their rates after conventional EVAR are known to be more common after treatment of adverse aneurysm anatomy, outside of the manufacturer IFU [18,19]. Early experience suggests that complications also occur using the Nellix device in patients where the proximal neck and distal iliac artery anatomy falls outside of the manufacturer’s IFU [20]. Examples of complications after use of the Nellix device, more common in aneurysms that fall outside the IFU, are presented in Table 3.

Experience to date indicates reduced endoleaks occurrence, especially type 2, of Nellix compared with conventional EVAR. The Nellix endobag both anchors the device and obliterates the potential space for blood flow into the aneurysm sac. Only one type 2 endoleaks and two type 1 endoleaks have been identified in the literature to date. The type 2 endoleaks resolved spontaneously within 60 days of detection.
Of the type 1 endoleaks, one proximal type 1a endoleak resolved spontaneously between CT scans performed 1 and 2 months after insertion. The other, persistent distal type 1b endoleaks (secondary to long aneurysm sac incompletely filled by the endobag), was successfully treated with an iliac extender and internal iliac artery embolization at 15 months [15,20]. Similarly, in our experience a simple covered iliac stent has been used to successfully treat a persistent iliac artery aneurysm following Nellix abdominal aortic aneurysm repair (Table 3 and Figure 5). The spontaneous resolution of some type 1 endoleaks following Nellix insertion, with no increase in sac size in the reported series to date, brings into question both the long term behavior of these endoleaks and hence their appropriate management (Figure 6).

Other potential complications include renal artery stenosis due to encroachment by the endobag (Figure 7), unilateral endografts luminal stenosis (Figure 8), and Nellix limb thrombosis (Figure 9) [18]. Currently, the frequency and long term behavior of endoleaks, limb kinking, partial renal artery occlusion and Nellix limb occlusion

<table>
<thead>
<tr>
<th>Complication observed</th>
<th>Months after device insertion</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Type 1a endoleak (Figure 6)</td>
<td>3</td>
<td>Embolisation of endoleak sac with Onyx</td>
</tr>
<tr>
<td>Renal artery stenosis following partial occlusion by the endobag (Figure 7)</td>
<td>2</td>
<td>Endovascular stenting of the affected renal artery</td>
</tr>
<tr>
<td>Nellix limb kinking distally (Figure 8)</td>
<td>Immediate</td>
<td>Endovascular iliac limb stent placement</td>
</tr>
<tr>
<td>Nellix graft limb occlusion. (Figure 9)</td>
<td>3.5</td>
<td>None</td>
</tr>
</tbody>
</table>

Table 3: Examples of complications observed at our institution after Nellix EVAS.

Figure 5: Iliac artery extension of a right iliac artery aneurysm following Nellix treatment of an infrarenal abdominal aortic aneurysm. (a) Coronal CT aortogram demonstrates a successfully stented aortic aneurysm. (b) The known right common iliac aneurysm sac was subsequently covered with a right iliac endograft extension stent.

Figure 6: Type 1a endoleak. (a) Axial CT aortogram performed shortly after Nellix deployment. An area of high density anterior to the proximal graft may represent an endoleak or high density polymer within the Nellix endobag. (b) 3 months later, the polymer within the endobag has reduced in density and a small Type 1a endoleak is clearly evident. (c) Digital subtraction angiography image showing successful endovascular embolization of the endoleak with Onyx. (d) Subsequent axial CT aortogram demonstrates no residual filling of the endoleak, which is occluded with Onyx.

Figure 7: Renal artery stenosis following Nellix stent insertion. (aandb) Coronal and axial CT aortograms performed 2 days post-procedure demonstrate patent renal arteries on both sides. (candd) Corresponding CT images 2 months later show >75% stenosis of the proximal left renal artery. (e) Conventional angiogram confirms stenosis of the proximal left renal artery. (f) successfully treated by endovascular stenting.
increasing use of the Nellix EVAS, radiologists are likely to encounter patients undergoing follow-up CT scans after Nellix EVAR in their daily practice. In this pictorial review, we have presented the standard imaging features of this device and have presented illustrative examples of complications that can occur.

References